Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2016
|
| オンライン･アクセス: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|